Skip to content
naulon
Not checkedNot checked for notices yet.

Gαs, adenylyl cyclase, and their relationship to the diagnosis and treatment of depression

Jeffrey M. Schappi, Jeffrey M. Schappi, Mark M. Rasenick and 3 more

Frontiers in Pharmacology · 2022

doi:10.3389/fphar.2022.1012778 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The relationship between depression, its etiology and therapy, and the cAMP signaling system have been studies for decades. This review will focus on cAMP, G proteins and adenylyl cyclase and depression or antidepressant action. Both human and animal studies are compared and contrasted. It is concluded that there is some synteny in the findings that cAMP signaling is attenuated in depression and that this is reversed by successful antidepressant therapy. The G protein that activates adenylyl cyclase, Gαs, appears to have diminished access to adenylyl cyclase in depression, and this is rectified by successful antidepressant treatment. Unfortunately, attempts to link specific isoforms of adenylyl cyclase to depression or antidepressant action suffer from discontinuity between human and animal studies.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.